Intertek Launches Unique Pharmaceutical NMR
News Jul 24, 2014
The facility is Good Manufacturing Practice (cGMP) compliant and available through Intertek’s existing centre of excellence for NMR spectroscopy and analytical services, located in Manchester, UK.
The installation of a new 600MHz Bruker Ascend spectrometer with CryoProbeTM functionality provides high sensitivity analysis for a wide range of pharmaceutical applications. The data generated can be used by pharmaceutical clients to support their regulatory submissions and chemistry, manufacturing and controls (CMC) activities including product characterisation, stability, commercial release testing and identification and quantification of low level impurities and process residuals. Clients involved in biopharmaceutical product development will benefit from regulatory NMR data supporting protein characterisation.
Ashleigh Wake, Biotechnology Programme Manager shared “The impressive sensitivity of the new high resolution instrument coupled with GMP compliance and our NMR team’s expertise enables us to provide the highest quality of data for our client’s regulatory requirements.”
Chetan Parmar, Senior Vice President of Intertek Life Sciences, said “This new GMP regulated NMR capability forms a one-of-a-kind NMR contract analysis service. It once again demonstrates Intertek’s continued commitment to provide world class regulatory analytical services supporting our global clients who are developing evermore complex and challenging pharmaceutical products.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018